CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTMX POWR Grades
- Value is the dimension where CTMX ranks best; there it ranks ahead of 90.38% of US stocks.
- The strongest trend for CTMX is in Momentum, which has been heading down over the past 31 weeks.
- CTMX ranks lowest in Momentum; there it ranks in the 9th percentile.
CTMX Stock Summary
- Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 14.18% of US stocks have a lower such ratio.
- For CTMX, its debt to operating expenses ratio is greater than that reported by just 16.71% of US equities we're observing.
- CytomX Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -33.26%, greater than the shareholder yield of just 8.58% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to CytomX Therapeutics Inc, a group of peers worth examining would be WVE, PTCT, CHRS, DTIL, and KPTI.
- CTMX's SEC filings can be seen here. And to visit CytomX Therapeutics Inc's official web site, go to www.cytomx.com.
CTMX Valuation Summary
- CTMX's price/sales ratio is 5.4; this is 54.43% lower than that of the median Healthcare stock.
- CTMX's price/sales ratio has moved down 55.9 over the prior 70 months.
- Over the past 70 months, CTMX's EV/EBIT ratio has gone up 15.
Below are key valuation metrics over time for CTMX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CTMX | 2021-03-17 | 5.5 | 11.0 | -16.7 | -8.1 |
| CTMX | 2020-07-31 | 4.1 | 4.6 | -4.2 | -2.2 |
| CTMX | 2020-07-24 | 4.6 | 5.1 | -4.7 | -2.6 |
| CTMX | 2020-06-30 | 4.9 | 5.5 | -5.0 | -2.9 |
| CTMX | 2018-12-03 | 8.6 | 4.1 | -12.4 | -8.1 |
| CTMX | 2016-09-06 | 50.3 | 4.6 | -8.2 | -7.8 |
CTMX Price Target
For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.94 | Average Broker Recommendation | 1.59 (Moderate Buy) |
CTMX Stock Price Chart Interactive Chart >
CTMX Price/Volume Stats
| Current price | $5.41 | 52-week high | $10.05 |
| Prev. close | $5.55 | 52-week low | $5.31 |
| Day low | $5.38 | Volume | 349,700 |
| Day high | $5.56 | Avg. volume | 940,379 |
| 50-day MA | $6.61 | Dividend yield | N/A |
| 200-day MA | $7.46 | Market Cap | 351.71M |
CytomX Therapeutics, Inc. (CTMX) Company Bio
CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.
Latest CTMX News From Around the Web
Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and web |
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOsHere''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) (announced a collaboration with Biovac to manufacture COVID-19 shots in South Africa) Bristol-Myers Squibb Company (NYSE: BMY ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Century Therapeutics, Inc. (NASDAQ: IPSC ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced positive data for pipeline asset in periodontal disease) Eli Lilly and Company (NYSE: LLY ) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) (reacted to its second-quarter results) Novo Nordisk A/... |
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall StreetHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena P... |
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOsHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: A... |
CTMX Price Returns
| 1-mo | -13.30% |
| 3-mo | -43.05% |
| 6-mo | -29.56% |
| 1-year | -22.82% |
| 3-year | -78.91% |
| 5-year | -46.65% |
| YTD | -17.40% |
| 2020 | -21.18% |
| 2019 | -44.97% |
| 2018 | -28.47% |
| 2017 | 92.08% |
| 2016 | -47.34% |
Continue Researching CTMX
Want to do more research on CytomX Therapeutics Inc's stock and its price? Try the links below:CytomX Therapeutics Inc (CTMX) Stock Price | Nasdaq
CytomX Therapeutics Inc (CTMX) Stock Quote, History and News - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...